Active Pharmaceutical Ingredients - Dr Reddy's
Active Pharmaceutical Ingredients - Dr Reddy's

About Suzetrigine API

Product
  • Therapeutic Category 疼痛管理

  • CAS Number

    2649467‑58‑1

  • API Technology

    Small‑molecule synthetic API

  • Dose Form

    Tablets

  • Dr Reddy's Development Status

    Under Development

Mechanism of action 

Suzetrigine selectively inhibits the Naᵥ1.8 voltage‑gated sodium channel, which is predominantly expressed in peripheral pain‑sensing (nociceptive) neurons of the dorsal root ganglia.
It binds to the second voltage‑sensing domain (VSD2) of Naᵥ1.8 and stabilizes the channel in a closed (inactive) state.


Indication 

Approved indication (FDA):

Treatment of moderate to severe acute pain in adults

 

Request for Quotation

Get in touch with us by filling out the form below. Our team will reach out to you shortly!

Phone
Country *
Select Product *
Select Regulatory Requirements
Select Purpose

Related APIs

エラゴリクスナトリウム

疼痛管理

arrow

ナプロキセンナトリウム

疼痛管理

arrow

ナラトリプタン塩酸塩

疼痛管理

arrow

スマトリプタンコハク酸塩

疼痛管理

arrow

ケトロラク・トロメタミン

疼痛管理

arrow

ナプロキセン

疼痛管理

arrow

免責事項

No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

Disclaimer: Products under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act (Bolar Exemption) and not for commercial sale.